scispace - formally typeset
P

Patompong Ungprasert

Researcher at Cleveland Clinic

Publications -  311
Citations -  5893

Patompong Ungprasert is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Meta-analysis & Odds ratio. The author has an hindex of 31, co-authored 295 publications receiving 4041 citations. Previous affiliations of Patompong Ungprasert include Mayo Clinic & Siriraj Hospital.

Papers
More filters
Journal ArticleDOI

Acetazolamide Therapy in Patients with Heart Failure: A Meta-Analysis.

TL;DR: A study demonstrates significant reduction in serum pH, increase in natriuresis, and improvements in apnea indexes with use of acetazolamide among HF patients.
Journal ArticleDOI

Smoking and Risk of Microscopic Colitis: A Systematic Review and Meta-analysis

TL;DR: The current systematic review and meta-analysis found a significantly higher risk of microscopic colitis among current smokers compared with never-smokers, and the risk attenuated among former smokers but remained significantly higher among never-Smokers.
Journal ArticleDOI

Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis.

TL;DR: A significantly increased risk of albuminuria among patients with NAFLD was observed in this meta-analysis and Physicians should pay more attention to the early detection and subsequent treatment of individuals with microalbuminuria especially in patients withNAFLD.
Journal ArticleDOI

Changes in bone mineral density and bone metabolism after sleeve gastrectomy: a systematic review and meta-analysis

TL;DR: The present study found a decreased BMD among patients with obesity after SG, and there were significant increases in serum calcium, serum 25-hydroxyvitamin D, and serum phosphate.
Journal ArticleDOI

Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis

TL;DR: It is found that patients with PsA who experience inadequate response or intolerance of traditional DMARDs or NSAIDs have a higher probability of achieving the ACR20 response with older TNF inhibitors and secukinumab.